A study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...

Considering all of the data and their limitations, questions still remain regarding the optimal treatment of COPD exacerbations ... only head-to-head trial to date. It is reasonable to recommend ...

China approves GSK's Nucala for chronic rhinosinusitis with nasal polyps, adding to its existing uses in asthma and other ...

Combined airway valve therapy in severe emphysema improves lung function and walking distance for patients with heterogeneous disease, despite some risks.

The major findings of this study of exacerbations of COPD can be ... few days after treatment initiation rather than at 5 or 10 days; however, this has not been studied to date and was not ...

GlaxoSmithKline (GSK) has announced full results from the Salford Lung Study (SLS), a pioneering study of COPD treatment aimed ... rate of moderate or severe exacerbations by 8.4% compared to ...

COPD could open up a massive ... make them suitable for treatment with Nucala. Elevated eosinophil levels are associated with more severe COPD and a higher rate of exacerbations, the sudden ...

Exceeds the Upper End of Guidance Range for Full-Year 2024 with Unaudited Global Revenues of Approximately $363.7 Million-- --2025 Global ARIKAYCE Revenues Expected to be Between $405 Million ...

For individuals with chronic lung conditions, the winter season and the current cold snap poses significant challenges. We ...

or are currently out of date. Therefore, the objective of this Cochrane systematic review was to evaluate the effectiveness of IDM COPD programmes on the most relevant patient-reported outcomes: ...

Winter seems to worsen the symptoms of asthma and COPD ... staying up-to-date with vaccinations, and consulting health care providers will help minimize risks of respiratory exacerbations and ...